Search

Merged into Armata 2019. Checked 2026-10-03. Historical Armata predecessor company. company US Merged into Armata in 2019.

Ceased operations 2023. Checked 2026-10-03. Former US parent of Phage Therapy Center LTD, Georgia. company US Ceased operations in 2023.

Acquired by AmpliPhi in 2012. Checked 2026-10-03. Historical phage-development company. company AU Acquired by AmpliPhi in 2012.

Official referral/inquiry route. Checked 2026-10-03. Spinal cord injury E. coli bacteriuria; personalized intravesical phage/placebo research. Houston, Texas; United States treating-center US Recruiting NCT06559618 Houston site lists Eva Am

Intake unconfirmed. Checked 2026-10-03. Personalized therapy for refractory/resistant infections; July 2026 Hebrew University announcement identifies current center leaders and planned P PEAKS UTI participation for recurrent E. coli infecti

Research/development. Checked 2026-10-03. In-vitro phage therapeutic/disinfectant research against MDR A. baumannii; clinical isolates are not human phage administration. New Delhi; India research-only IN Primary laboratory study and clinic

Intake unconfirmed. Checked 2026-10-03. Customized topical phages for infected pressure ulcers in an ICU cohort; wider wound-infection clinical research leads remain separate from access. Varanasi; India treating-center IN Primary 2026 pres

Research/development. Checked 2026-10-03. Human phage-derived protein/lysin antibacterials including P128; company states whole-bacteriophage applications shifted to nonhuman food, veterinary, environmental and agriculture markets in 2007.

Research/development. Checked 2026-10-03. E. coli/Vibrio phage research and bacterial-genome characterization. Chandigarh; India research-only IN Official faculty profile lists bacteriophage microbiology publications. No verified phage-spec

Research/development. Checked 2026-10-03. Phage-based microbial therapeutic discovery and development; diagnostic/research services. India company IN Company presents AMR research, diagnostics, shared facilities and hospital partnerships; s

Website active; facilitator. Checked 2026-10-03. Facilitation for antibiotic-resistant bacterial infections; provider/treatment decisions belong to treating physicians and partner institutions. India facilitator IN Website contact form, con

Official referral/inquiry route. Checked 2026-10-03. Supplier expanded access plus EcoActive, ShigActive and VRELysin clinical development; fixed indications and product availability limit access. Columbia, Maryland; United States supplier

Intake unconfirmed. Checked 2026-10-03. Adult COVID-19-associated secondary pneumonia and pediatric ventilator-associated pneumonia prevention studies; Razi hospital affiliation appears in adult study. Iran treating-center IR Primary clinic

Research/development. Checked 2026-10-03. Institutional 2021 report on Helicobacter pylori phage research; candidate isolation work rather than a clinical treatment program. Bogotá; Colombia research-only CO No human phage therapy inquiry r

Intake unconfirmed. Checked 2026-10-03. EcoActive oral E. coli phage preparation for adults with inactive Crohn's and intestinal adherent-invasive E. coli. Baltimore, Maryland; United States treating-center US Sponsor page lists Maryland re

Research/development. Checked 2026-10-03. AMR-oriented phage drug discovery, bacterial surveillance and engineered phage/capsid approaches. Shimotsuke; Japan research-only JP Official laboratory research pages describe phage drug discovery

Research/development. Checked 2026-10-03. Microbiome/pathobiont targeting, phage-derived lytic enzymes, clinical translation. jRCTs051230164 is hosted clinically at Osaka Metropolitan University Hospital. Suita; Japan research-only JP Offic

Intake unconfirmed. Checked 2026-10-03. Topical whole-bacteriophage gel for acne vulgaris twice daily for84days; target15, ages>=12. Native registry displays registration12/01/2024 and first enrollment03/07/2024 without resolving date-forma

Research/development. Checked 2026-10-03. Phage cocktail research and technical/ethical preparation for clinical implementation. Tokyo; Japan research-only JP Official institute page presents phage-library, engineering, animal-study and imp

Research/development. Checked 2026-10-03. Phage research intended to complement AMR control and future therapeutics. Nairobi; Kenya research-only KE Official KEMRI material discusses phage AMR research, resource-bank and regulatory capacity